⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma

Official Title: Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma

Study ID: NCT00086801

Conditions

Lymphoma

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy, such as doxorubicin, vinblastine, and gemcitabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed stage I or stage II Hodgkin's lymphoma.

Detailed Description: OBJECTIVES: Primary * Determine the complete response rate in patients with newly diagnosed stage IA, IB, IIA, or IIB non-bulky Hodgkin's lymphoma treated with doxorubicin, vinblastine, and gemcitabine. Secondary * Determine the event-free survival of patients treated with this regimen. * Determine the toxicity of this regimen in these patients. * Determine whether fludeoxyglucose F 18 positron-emission tomography scanning is useful in predicting clinical relapse and determining the presence of residual disease in these patients after treatment with this regimen. OUTLINE: This is a multicenter study. Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and gemcitabine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients undergo fludeoxyglucose F 18 positron-emission tomography (PET) scanning and CT scan before treatment and after courses 2 and 6 of therapy to assess response. Patients with a positive PET scan after completion of study therapy may undergo biopsy. A PET scan is performed 3 months later if biopsy is negative or biopsy is unable to be performed. Patients are followed every 3 months for 1 year, every 4 months for 2 years, every 6 months for 2 years, and then annually for 5 years.

Eligibility

Minimum Age: 16 Years

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

UCSF Comprehensive Cancer Center, San Francisco, California, United States

Beebe Medical Center, Lewes, Delaware, United States

CCOP - Christiana Care Health Services, Newark, Delaware, United States

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States

Walter Reed Army Medical Center, Washington, District of Columbia, United States

University of Chicago Cancer Research Center, Chicago, Illinois, United States

Elkhart General Hospital, Elkhart, Indiana, United States

Howard Community Hospital at Howard Regional Health System, Kokomo, Indiana, United States

Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States

CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

Memorial Hospital of South Bend, South Bend, Indiana, United States

Saint Joseph Regional Medical Center, South Bend, Indiana, United States

Iowa Blood and Cancer Care, Cedar Rapids, Iowa, United States

St. Luke's Hospital, Cedar Rapids, Iowa, United States

Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

Union Hospital Cancer Center at Union Hospital, Elkton MD, Maryland, United States

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, United States

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph, St. Joseph, Michigan, United States

University of Minnesota Medical Center - Fairview, Minneapolis, Minnesota, United States

Missouri Cancer Associates, Columbia, Missouri, United States

Siteman Cancer Center at Barnes-Jewish Hospital, St Louis, Missouri, United States

Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center, Grand Island, Nebraska, United States

Great Plains Regional Medical Center, North Platte, Nebraska, United States

UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States

Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States

Roswell Park Cancer Institute, Buffalo, New York, United States

Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States

CCOP - Hematology-Oncology Associates of Central New York, Syracuse, New York, United States

SUNY Upstate Medical University Hospital, Syracuse, New York, United States

Community General Hospital, Syracuse, New York, United States

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, United States

Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States

Wayne Radiation Oncology, Goldsboro, North Carolina, United States

Lenoir Memorial Cancer Center, Kinston, North Carolina, United States

Wilson Medical Center, Wilson, North Carolina, United States

Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States

Bon Secours St. Francis Health System, Greenville, South Carolina, United States

CCOP - Greenville, Greenville, South Carolina, United States

Mountainview Medical, Berlin, Vermont, United States

Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States

Contact Details

Name: David Straus, MD

Affiliation: Memorial Sloan Kettering Cancer Center

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: